These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
908 related articles for article (PubMed ID: 9399211)
1. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
2. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230 [TBL] [Abstract][Full Text] [Related]
3. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. Haber SN; Ryoo H; Cox C; Lu W J Comp Neurol; 1995 Nov; 362(3):400-10. PubMed ID: 8576447 [TBL] [Abstract][Full Text] [Related]
4. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats]. Wang S; Qi XJ; Han D Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498 [TBL] [Abstract][Full Text] [Related]
5. Reduced gene expression for dopamine biosynthesis and transport in midbrain neurons of adult male rats exposed prenatally to ethanol. Szot P; White SS; Veith RC; Rasmussen DD Alcohol Clin Exp Res; 1999 Oct; 23(10):1643-9. PubMed ID: 10549997 [TBL] [Abstract][Full Text] [Related]
6. Akt signal transduction dysfunction in Parkinson's disease. Timmons S; Coakley MF; Moloney AM; O' Neill C Neurosci Lett; 2009 Dec; 467(1):30-5. PubMed ID: 19800394 [TBL] [Abstract][Full Text] [Related]
7. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion. Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980 [TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880 [TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189 [TBL] [Abstract][Full Text] [Related]
10. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. Kanaan NM; Kordower JH; Collier TJ J Comp Neurol; 2007 Jun; 502(5):683-700. PubMed ID: 17436290 [TBL] [Abstract][Full Text] [Related]
11. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Ryoo HL; Pierrotti D; Joyce JN Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases. Goto S; Hirano A; Matsumoto S Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418 [TBL] [Abstract][Full Text] [Related]
14. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
15. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism. Rothblat DS; Schroeder JA; Schneider JS J Neurosci Res; 2001 Aug; 65(3):254-66. PubMed ID: 11494360 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
17. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855 [TBL] [Abstract][Full Text] [Related]
18. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine. Iwata SI; Nomoto M; Fukuda T Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626 [TBL] [Abstract][Full Text] [Related]